Stay updated on Pembrolizumab & ATRA combo in Adv. Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & ATRA combo in Adv. Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab & ATRA combo in Adv. Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study record for pembrolizumab plus all-trans retinoic acid in advanced melanoma is displayed, including its completed status, eligibility criteria, treatment plan, outcome measures, and study dates.SummaryDifference52%

- Check17 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide banner announces NIH’s transition from using “artificial intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision label updates from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study content, showing the 403 header and related HTML. The visible navigation includes a Home link and revision information, replacing the former study documents and data sections.SummaryDifference19%

Stay in the know with updates to Pembrolizumab & ATRA combo in Adv. Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & ATRA combo in Adv. Melanoma Clinical Trial page.